Intec Pharma Ltd.
(NASDAQ : NTEC)

( )
NTEC After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
2.06%21.3314.1%$125.51m
MDCOMedicines Company
1.72%53.0920.3%$104.73m
GWPHGW Pharmaceuticals PLC Sponsored ADR
3.55%120.336.2%$95.99m
AMRNAmarin Corporation Plc Sponsored ADR
2.65%15.861.8%$84.76m
JAZZJazz Pharmaceuticals Plc
0.34%118.052.3%$59.26m
SAGESAGE Therapeutics, Inc.
3.54%144.268.6%$55.96m
PRGOPerrigo Co. Plc
1.45%53.826.8%$52.09m
PCRXPacira Pharmaceuticals, Inc.
4.07%38.1010.5%$45.60m
UTHRUnited Therapeutics Corporation
0.89%81.9714.3%$39.43m
CTLTCatalent Inc
1.84%49.232.4%$35.25m
HZNPHorizon Pharma plc
3.35%28.206.6%$35.07m
ICLRICON Plc
0.27%141.024.1%$32.80m
ICPTIntercept Pharmaceuticals, Inc.
5.62%64.2516.9%$32.03m
AERIAerie Pharmaceuticals, Inc.
2.92%20.286.8%$28.14m
AXSMAxsome Therapeutics, Inc.
13.10%20.632.0%$25.52m

Company Profile

Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which focuses on developing drugs based on its proprietary Accordion Pill platform technology. Its product pipeline includes four product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients; Accordion Pill Zaleplon, which is being developed for the treatment of insomnia, including sleep induction and the improvement of sleep maintenance; an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel Nonsteroidal Anti-Inflammatory Drug which induces ulcers; and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol and tetrahydrocannabinol, which is being developed for various indications including low back neuropathic pain and fibromyalgia. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.